Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function
Information source: Creighton University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertension
Intervention: Chlorthalidone 12.5 mg (Drug); Hydrochlorothiazide 25 mg (Drug); Placebo (Drug)
Phase: Phase 4
Status: Withdrawn
Sponsored by: Creighton University Official(s) and/or principal investigator(s):
Ahmed Aboeata, MBBCh, Principal Investigator, Affiliation: Creighton University
Summary
Chlorthalidone will result in improved endothelial function compared to hydrochlorothiazide
as measured by flow mediated vasodilatation.
Clinical Details
Official title: The Effect of Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function in Hypertensive Patients: A Pilot Study
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Flow mediated vasodilatation
Detailed description:
This is a randomized, double-blind, crossover study to evaluate chlorthalidone and
hydrochlorothiazide and their effects on endothelial function in hypertensive patients.
Subjects will receive chlorthalidone 12. 5 mg, hydrochlorothiazide 25 mg, and placebo each
for 4 weeks with a 1 week washout between study periods. Sequence of study drugs will be
randomized. Flow mediated vasodilatation will be measured at baseline and after each
treatment period.
Eligibility
Minimum age: 19 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age 19 or older
- Diagnosis of hypertension
- Current blood pressure > 120/80 mm Hg
Exclusion Criteria:
- Use of a thiazide-type diuretic within the last 1 month
- Known allergy to any study medications
- History of gout or hyperuricemia
- SCr >/= 1. 8 mg/dl or CrCl < 25 ml/min
- Pregnancy or breastfeeding or planning to become pregnant during study period
- Dementia or cognitive impairment
- Hypokalemia
- Acute coronary syndrome or stroke within 6 months
- Current use of sildenafil, tadalafil, or vardenafil
Locations and Contacts
Creighton University, Omaha, Nebraska 68131, United States
Additional Information
Starting date: March 2013
Last updated: March 24, 2015
|
